Cargando…
Pathway-based dissection of the genomic heterogeneity of cancer hallmarks’ acquisition with SLAPenrich
Cancer hallmarks are evolutionary traits required by a tumour to develop. While extensively characterised, the way these traits are achieved through the accumulation of somatic mutations in key biological pathways is not fully understood. To shed light on this subject, we characterised the landscape...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5928049/ https://www.ncbi.nlm.nih.gov/pubmed/29713020 http://dx.doi.org/10.1038/s41598-018-25076-6 |
_version_ | 1783319160067981312 |
---|---|
author | Iorio, Francesco Garcia-Alonso, Luz Brammeld, Jonathan S. Martincorena, Iňigo Wille, David R. McDermott, Ultan Saez-Rodriguez, Julio |
author_facet | Iorio, Francesco Garcia-Alonso, Luz Brammeld, Jonathan S. Martincorena, Iňigo Wille, David R. McDermott, Ultan Saez-Rodriguez, Julio |
author_sort | Iorio, Francesco |
collection | PubMed |
description | Cancer hallmarks are evolutionary traits required by a tumour to develop. While extensively characterised, the way these traits are achieved through the accumulation of somatic mutations in key biological pathways is not fully understood. To shed light on this subject, we characterised the landscape of pathway alterations associated with somatic mutations observed in 4,415 patients across ten cancer types, using 374 orthogonal pathway gene-sets mapped onto canonical cancer hallmarks. Towards this end, we developed SLAPenrich: a computational method based on population-level statistics, freely available as an open source R package. Assembling the identified pathway alterations into sets of hallmark signatures allowed us to connect somatic mutations to clinically interpretable cancer mechanisms. Further, we explored the heterogeneity of these signatures, in terms of ratio of altered pathways associated with each individual hallmark, assuming that this is reflective of the extent of selective advantage provided to the cancer type under consideration. Our analysis revealed the predominance of certain hallmarks in specific cancer types, thus suggesting different evolutionary trajectories across cancer lineages. Finally, although many pathway alteration enrichments are guided by somatic mutations in frequently altered high-confidence cancer genes, excluding these driver mutations preserves the hallmark heterogeneity signatures, thus the detected hallmarks’ predominance across cancer types. As a consequence, we propose the hallmark signatures as a ground truth to characterise tails of infrequent genomic alterations and identify potential novel cancer driver genes and networks. |
format | Online Article Text |
id | pubmed-5928049 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-59280492018-05-07 Pathway-based dissection of the genomic heterogeneity of cancer hallmarks’ acquisition with SLAPenrich Iorio, Francesco Garcia-Alonso, Luz Brammeld, Jonathan S. Martincorena, Iňigo Wille, David R. McDermott, Ultan Saez-Rodriguez, Julio Sci Rep Article Cancer hallmarks are evolutionary traits required by a tumour to develop. While extensively characterised, the way these traits are achieved through the accumulation of somatic mutations in key biological pathways is not fully understood. To shed light on this subject, we characterised the landscape of pathway alterations associated with somatic mutations observed in 4,415 patients across ten cancer types, using 374 orthogonal pathway gene-sets mapped onto canonical cancer hallmarks. Towards this end, we developed SLAPenrich: a computational method based on population-level statistics, freely available as an open source R package. Assembling the identified pathway alterations into sets of hallmark signatures allowed us to connect somatic mutations to clinically interpretable cancer mechanisms. Further, we explored the heterogeneity of these signatures, in terms of ratio of altered pathways associated with each individual hallmark, assuming that this is reflective of the extent of selective advantage provided to the cancer type under consideration. Our analysis revealed the predominance of certain hallmarks in specific cancer types, thus suggesting different evolutionary trajectories across cancer lineages. Finally, although many pathway alteration enrichments are guided by somatic mutations in frequently altered high-confidence cancer genes, excluding these driver mutations preserves the hallmark heterogeneity signatures, thus the detected hallmarks’ predominance across cancer types. As a consequence, we propose the hallmark signatures as a ground truth to characterise tails of infrequent genomic alterations and identify potential novel cancer driver genes and networks. Nature Publishing Group UK 2018-04-30 /pmc/articles/PMC5928049/ /pubmed/29713020 http://dx.doi.org/10.1038/s41598-018-25076-6 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Iorio, Francesco Garcia-Alonso, Luz Brammeld, Jonathan S. Martincorena, Iňigo Wille, David R. McDermott, Ultan Saez-Rodriguez, Julio Pathway-based dissection of the genomic heterogeneity of cancer hallmarks’ acquisition with SLAPenrich |
title | Pathway-based dissection of the genomic heterogeneity of cancer hallmarks’ acquisition with SLAPenrich |
title_full | Pathway-based dissection of the genomic heterogeneity of cancer hallmarks’ acquisition with SLAPenrich |
title_fullStr | Pathway-based dissection of the genomic heterogeneity of cancer hallmarks’ acquisition with SLAPenrich |
title_full_unstemmed | Pathway-based dissection of the genomic heterogeneity of cancer hallmarks’ acquisition with SLAPenrich |
title_short | Pathway-based dissection of the genomic heterogeneity of cancer hallmarks’ acquisition with SLAPenrich |
title_sort | pathway-based dissection of the genomic heterogeneity of cancer hallmarks’ acquisition with slapenrich |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5928049/ https://www.ncbi.nlm.nih.gov/pubmed/29713020 http://dx.doi.org/10.1038/s41598-018-25076-6 |
work_keys_str_mv | AT ioriofrancesco pathwaybaseddissectionofthegenomicheterogeneityofcancerhallmarksacquisitionwithslapenrich AT garciaalonsoluz pathwaybaseddissectionofthegenomicheterogeneityofcancerhallmarksacquisitionwithslapenrich AT brammeldjonathans pathwaybaseddissectionofthegenomicheterogeneityofcancerhallmarksacquisitionwithslapenrich AT martincorenainigo pathwaybaseddissectionofthegenomicheterogeneityofcancerhallmarksacquisitionwithslapenrich AT willedavidr pathwaybaseddissectionofthegenomicheterogeneityofcancerhallmarksacquisitionwithslapenrich AT mcdermottultan pathwaybaseddissectionofthegenomicheterogeneityofcancerhallmarksacquisitionwithslapenrich AT saezrodriguezjulio pathwaybaseddissectionofthegenomicheterogeneityofcancerhallmarksacquisitionwithslapenrich |